Tran Minh T, Grosse Sandrine, Carbajo Rodrigo J, Jacoby Edgar, Yin Yanting, Yu Xiaodi, Martinez Carol, Stoops Bart, Cooymans Ludwig, Hu Lili, Lutter Ferdinand H, Pieters Serge, Tan Eric, Alcázar Jesus, Roymans Dirk, van Vlijmen Herman, Rigaux Peter, Sharma Sujata, Jonckers Tim H M
Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
Janssen Research and Development, Janssen-Cilag, S.A., C/Jarama 75, 45007 Toledo, Spain.
ACS Med Chem Lett. 2024 Aug 2;15(9):1549-1558. doi: 10.1021/acsmedchemlett.4c00272. eCollection 2024 Sep 12.
Despite the availability of medicines preventing respiratory syncytial virus (RSV) infection, post-exposure treatment options are needed for addressing patient's needs. RSV non-nucleoside polymerase inhibitors (NNI) have emerged as a promising asset for which our group previously disclosed JNJ-8003 with potent antiviral activity and pronounced efficacy. In this work, a structural-guided design to modify the linker vector of JNJ-8003 resulted in the identification of 2-oxacyclo pyridine-containing derivatives whose various ring closing strategies are described. In addition, bioisosteric replacement of an amide bond with triazole retained potency, and cryo-electron microscopy (cryo-EM) confirmed binding in the capping domain. Subsequent NMR conformational analysis suggested a correlation between the potency and conformations. Our efforts have fulfilled the aim of identifying linker modifications with maintained biological activity while enriching structural diversity and allowing modulations of other parameters.
尽管有预防呼吸道合胞病毒(RSV)感染的药物,但仍需要暴露后治疗方案来满足患者需求。RSV非核苷聚合酶抑制剂(NNI)已成为一种有前景的药物,我们团队之前已披露具有强效抗病毒活性和显著疗效的JNJ-8003。在这项工作中,通过结构导向设计对JNJ-8003的连接子载体进行修饰,从而鉴定出含2-氧杂环吡啶的衍生物,并描述了其各种环化策略。此外,用三唑对酰胺键进行生物电子等排体替代可保持活性,冷冻电子显微镜(cryo-EM)证实其在封端结构域中的结合。随后的核磁共振构象分析表明活性与构象之间存在相关性。我们的工作实现了识别具有维持生物活性的连接子修饰的目标,同时丰富了结构多样性并允许对其他参数进行调节。